Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Nov;90(1079):20170442.
doi: 10.1259/bjr.20170442.

The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis

Jc Kennetth Jacinto  1 , Jayson Co  1 , Michael Benedict Mejia  1 , Eugenio Emmanuel Regala  2
Affiliations
Meta-Analysis

The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis

Jc Kennetth Jacinto et al. Br J Radiol. 2017 Nov.

Abstract

Objective: This study aims to synthesize the current available evidences on the effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in the primary and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC).

Methods: A systematic review and meta-analysis of literature were undertaken to assess the effectiveness of weekly vs triweekly schedule in primary and adjuvant treatment for HNSCC with adverse risk features. Search of relevant articles from electronic database from 2000 to March 2016 and appraisal of studies were done.

Results: Only one randomized controlled trial (RCT) and six retrospective studies were included in this review. The RCT showed less severe mucositis (75 vs 38.5%, p = 0.012) and more patients receiving at least 200 mg/m2 (62.5% vs 88.5%, p = 0.047) of cisplatin in triweekly arm. There was no difference in 1-year progression-free survival (60% vs 71.1%, p = 0.806) and 1-year overall survival (OS) (71.6 vs 79.3%, p = 0.978) between the weekly and triweekly arm. Pooling of data from six studies showed no difference in 5-year progression-free survival (RR 0.84, 95%, CI 0.67-1.07), 5-year OS (RR 0.88, 95% CI 0.73-1.07), severe renal events (RR 0.66, 95% CI 0.42-1.04), severe mucositis (RR 0.92, 95% CI 0.71-1.21), severe dermatitis (RR 0.61, 95% CI 0.37-1.03), treatment interruptions (RR 1.06, 95% CI 0.74-1.52) and number of patients receiving at least 200 mg/m2 (RR 0.83, 95% CI 0.67-1.03).

Conclusion: The current evidence showed that weekly schedule is not superior to triweekly in improving oncological outcomes and decreasing early effects of treatment. In the absence of compelling data, triweekly schedule should remain the standard of care while more RCTs are warranted. Advances in knowledge: While some have proposed that low-dose weekly cisplatin is safer and less toxic, this study emphasized that there is no difference in acute toxicity of the two schedules and it is safe to utilize high-dose cisplatin every 3 weeks to reach the threshold dose of 200 mg/m2 faster. Uniquely, this study excluded nasopharyngeal cancer patients as the biology and treatment response are different with other HNSCC.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Preferred reporting items for systematic reviews and meta analyses flowchart.
Figure 2.
Figure 2.
Weekly vs triweekly cisplatin arm. Overall survival at 5-year follow up.
Figure 3.
Figure 3.
Weekly vs triweekly cisplatin arm. Progression-free survival at 5year follow up.
Figure 4.
Figure 4.
Weekly vs triweekly cisplatin arm. Occurrence of severe renal events.
Figure 5.
Figure 5.
Weekly vs triweekly cisplatin arm. Occurrence of severe mucositis.
Figure 6.
Figure 6.
Weekly vs triweekly cisplatin arm. Occurrence of severe dermatitis.
Figure 7.
Figure 7.
Weekly vs triweekly cisplatin arm. Number of patients with radiation treatment interruptions.
Figure 8.
Figure 8.
Weekly vs triweekly cisplatin arm. Number of patients receiving at least 200 mg/m2 cumulative cisplatin dose.
See this image and copyright information in PMC

References

    1. NationalComprehensive Cancer Network. Head and Neck Cancer (Version 2.2017). 2017. Available from: https://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf [Cited: 28 March 2017]
    1. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14. DOI: 10.1016/j.radonc.2009.04.014 - DOI - PubMed
    1. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100: 33–40. DOI: 10.1016/j.radonc.2011.05.036 - DOI - PubMed
    1. Nwizu T, Adelstein DJ. In squamous cell head and neck cancer: which platinum, how much and how often? Expert Rev Anticancer Ther 2014; 14: 1033–9. DOI: 10.1586/14737140.2014.924399 - DOI - PubMed
    1. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843–50. DOI: 10.1002/hed.20279 - DOI - PubMed

MeSH terms